

# CBDepot launches the sale of synthesized pharma-grade CBD

*CBDepot group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o.*

TEPLICE, CZECHIA, October 25, 2021 /EINPresswire.com/ -- During the CPhI 2017 event in Frankfurt, [CBDepot](#)

introduced, as the first company in the EU, [isolated GMP CBD](#) via 3rd party contract manufacturer from Prague. Since summer 2019, the group took on a project of relocation of API Cannabidiol manufacture to new premises of [CB21 Pharma](#) in Brno.



“

This addition will serve the GMP needs in applications or jurisdictions where the use of plant-based Cannabidiol API is not possible”

*Boris Bañas, group's Chief Sales Officer*

“This allows CB21 Pharma to bring to the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot”, says Dr. Jan Storch, the CEO of CB21 Pharma.

The now launched synthesized pharma-grade CBD is compliant with the German DAC monograph.

“This addition will serve the GMP needs in applications or jurisdictions where the use of plant-based Cannabidiol API

is not possible,” concludes Boris Bañas, group’s Chief Sales Officer.

Michal Tozser  
CBDepot  
+421 911920888

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554684333>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.